Rhodococcus Equi: Challenges to Treat Infections and to Mitigate Antimicrobial Resistance

J Equine Vet Sci. 2023 Aug:127:104845. doi: 10.1016/j.jevs.2023.104845. Epub 2023 Jun 7.

Abstract

Rhodococcus equi, a gram-positive facultative intracellular pathogen and a soil saprophyte, is one of the most common causes of pneumonia in young foals. It poses a threat to the economy in endemic horse-breeding farms and to animal welfare annually. Many farms use thoracic ultrasonographic screening and antimicrobial treatment of subclinically affected foals as a preventive measure against severe R. equi infections. The wide use antimicrobials to treat subclinically affected foals has contributed to the emergence of multidrug resistant (MDR)-R. equi in both clinical isolates from sick foals and in the environment of horse-breeding farms. Alternatives to treat foals infected with MDR-R. equi are scarce and the impact of the emergence of MDR-R. equi in the environment of farms is still unknown. The aim of this review is to discuss the emergence of MDR-R. equi in the United States and the challenges faced to guide antimicrobial use practices. Reduction of antimicrobial use at horse-breeding farms is essential for the preservation of antimicrobial efficacy and, ultimately, human, animal, and environmental health.

Keywords: Antimicrobial resistance; Equine; One health; Rhodococcus equi.

Publication types

  • Review

MeSH terms

  • Actinomycetales Infections* / drug therapy
  • Actinomycetales Infections* / veterinary
  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Bacterial
  • Horse Diseases* / drug therapy
  • Horse Diseases* / epidemiology
  • Horses
  • Humans
  • Rhodococcus equi*

Substances

  • Anti-Bacterial Agents

Supplementary concepts

  • Rhodococcus hoagii